



Advanced Enzyme Technologies Limited



This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section before taking any action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company undertakes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.

What are enzymes?

Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions.

Advanced uses enzymes to replace chemicals in, and improve efficiency of, a wide variety of industrial processes for its customers.



Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

What are Probiotics?

Probiotics are live microorganisms, when administered in sufficient amount, confer health benefits to human and animals. Probiotics have now become an integral part of several therapies for the digestive disorders and newer applications for treatment of several other diseases are being developed. Probiotics act by fighting with the disease causing microorganisms and by secreting beneficial metabolites in the human/animal system.

Advanced Enzymes has developed and upscaled technologies for the production and application of several important probiotics.

Mission



It is our mission to see that every human being is able to take advantage of the power of enzymes for well-being and leading a healthy life!

Vision



Our vision at Advanced Enzymes is to become the largest, enzyme-based, value provider to consumers and processors globally!



Manufacturing Units – 7


India - 5 USA - 2




R&D Units – 6

India – 4 | USA – 1 | Germany – 1


REVENUE (₹ mn)



EBIDTA (₹ mn)



PAT (₹ mn)



Indian enzyme company



Highest market share in India



Listed integrated enzyme player globally



68+

Enzymes & Probiotics



400+

Proprietary Products



700+

Customers Worldwide



45+

Countries Worldwide Presence



550+

Employees



7

Registered Patents



11

Food Enzyme Dossiers filed with EFSA



2*

GRAS Dossier evaluated by US FDA



420

m³ Fermentation Capacity






25+

Years of Fermentation Experience

Note: Facts & Figures as on 31st March 2020




*1 GRAS Dossier under evaluation with US FDA

Note: 2015: as per IGAAP | 2019: as per IndAs



Revenue Breakup ₹ in Million

*YoY Growth




Note: 1. On Consolidated Basis
2. PAT is before minority

3. Product categorywise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.


Q1FY21

Product Category-wise (%)



■ Animal HC ■ Human HC ■ Bio-Processing


Geographical Revenue Split (%)



■ Asia (ex- India) ■ Others ■ India ■ Europe ■ USA


Q1FY20

Product Category-wise (%)



■ Animal HC ■ Human HC ■ Bio-Processing

Geographical Revenue Split (%)



■ Asia (ex- India) ■ Others ■ India ■ Europe ■ USA

Note: 1. On Consolidated Basis

2. Segmental Revenue excluding excise duty

3. EBIDTA is including other income

4. Does not include sales made by evovx




5. PAT is before minority

6. Segment-wise revenue does not include other operating income

7. Ind AS adjustments are carried out on account of commission and discount.


₹ in Million except per share data

Particulars	Q1FY21 Unaudited	Q4FY20 Audited	Q1FY20 Unaudited	Y-o-Y (%)	FY20 Audited	FY19 Audited	Y-o-Y (%)
Income from Operations	1,105	1,103	1,103	0.2%	4,440	4,196	6%
Expenses	654	682	631	4%	2,675	2,587	3%
Profit from Operations before Other Income, Finance Costs and Exceptional Item	451	421	472	(4%)	1,765	1,609	10%
Other Income	52	18	11	373%	57	50	12%
Profit from ordinary activities before Finance Costs and Exceptional Item	503	439	483	4%	1,822	1,659	10%
Finance costs	5	7	8	(38%)	30	39	(23%)
Profit from ordinary activities before exceptional item and tax	498	432	475	5%	1,792	1,620	11%
Profit from ordinary activities before tax	498	432	475	5%	1,792	1,620	11%
Tax	150	105	135	11%	461	461	0%
Net Profit for the period	348	327	340	2%	1,330	1,159	15%
Earnings Per Share	3.13	2.80	2.99		11.58	9.95	



Revenue Breakup ₹ in Million

*YoY Growth




Note: 1. On Consolidated Basis
2. PAT is before minority

3. Segment-wise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.

FY20


Product Category-wise (%)



■ Animal HC ■ Human HC ■ Bio-Processing


FY19

Product Category-wise (%)




■ Animal HC ■ Human HC ■ Bio-Processing

Geographical Revenue Split (%)



■ Asia (ex- India) ■ Others ■ India ■ Europe ■ USA

Geographical Revenue Split (%)



■ Asia (ex- India) ■ Others ■ India ■ Europe ■ USA

Note: 1. On Consolidated Basis
2. PAT is before minority


3. Segment-wise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.


₹ in Million

Particulars	FY20 Audited	FY19 Audited
Assets		
Property, plant and equipment	2,042	1,618
Capital work-in-progress	101	105
Intangible assets	646	622
Goodwill	2,941	2,715
Other non-current assets	195	183
Current assets	3,813	2,820
Assets held for sale	48	48
Total Assets	9,786	8,111
Equity And Liabilities		
Equity share capital	223	223
Other equity	8,173	6,565
Non-controlling interest	278	260
Non-current liabilities	461	358
Current liabilities	596	651
Liabilities classified as held for sale	55	54
Total – Equity and Liabilities	9,786	8,111


₹ in Million




CAGR=10.87%



CAGR=9.84%



CAGR=10.95%




CAGR=14.72%

Note: As per IGAAP | FY17, FY18, FY19 – as per IndAs


All numbers are on Consolidated basis

ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax , Exceptional and extraordinary items + Finance cost) / Average (Net debt + Network)


Net Working Capital (Days)




Net Worth (₹ mn)



ROE (%) & ROCE (%)



Net Debt to Equity (x)



Note: As per IGAAP | FY17, FY18 & FY19 – as per IndAs

All numbers are on Consolidated basis

Net working capital days = $((\text{Trade receivables} + \text{inventories} - \text{Trade payables}) / \text{Revenue from operations}) * 365$

Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent

Stock Data (As on 11th August 2020)

 Market Capitalization (₹)	23,424 mn
 Shares Outstanding	111.67 mn
 Free Float	5.91 mn
 Symbol (NSE/ BSE)	ADVENZYMES / 540025

Stock Chart (As on 11th August 2020)




Source: BSE, NSE, Thomson Reuters

Top 5 Institutional Holders (As on 07th August 2020)

Institutions	OS (%)
ORBIMED ASIA III MAURITIUS	12.09
HDFC SMALL CAP FUND	6.51
RELIANCE CAPITAL TRUSTEE CO.	0.68
UTI – HEALTHCARE FUND	0.40
DFA INVESTMENT DIMENSIONS GROUP INC.	0.29

Shareholding Pattern (%)



Note: Data mentioned in above chart is as on 30th Jun 2020

Thank You

Advanced Enzyme Technologies Limited

Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India

Tel: +91-22-4170 3200

Web: www.advancedenzymes.com

Fax: + 91-22-25835159

